Randomized Phase III Trial Evaluating the Importance of Nephrectomy in Patients Presenting With Metastatic Renal Cell Carcinoma Treated With Sunitinib

Trial Profile

Randomized Phase III Trial Evaluating the Importance of Nephrectomy in Patients Presenting With Metastatic Renal Cell Carcinoma Treated With Sunitinib

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 10 Nov 2017

At a glance

  • Drugs Sunitinib (Primary)
  • Indications Renal cell carcinoma
  • Focus Registrational; Therapeutic Use
  • Acronyms CARMENA
  • Most Recent Events

    • 06 Nov 2017 Status changed from recruiting to active, no longer recruiting.
    • 12 Nov 2015 Planned End Date changed from 1 Feb 2018 to 1 Feb 2020 as reported by ClinicalTrials.gov record.
    • 12 Nov 2015 Planned primary completion date changed from 1 Sep 2017 to 1 Sep 2019 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top